Investor Presentaiton

Investor presentation First three months of 2017 Slide 49 Solid TresibaⓇ performance strengthens basal insulin market share in Japan Japanese basal value market shares TresibaⓇ Levemir® --- Japanese total insulin value market shares Eli Lilly Sanofi NN Total Basal - NPH - biosimilar glargine 80% glargine U100- - glargine U300. Novo Nordisk 70% 60% 50% 40% 30% 20% 10% 0% Feb 2014 Source: IMS Monthly February, 2017 value figures changing diabetes® 60% 49% 40% 40% 24% 13% 20% 12% 7% 3% 0% Feb 2017 Feb 2014 Source: IMS Monthly February, 2017 value figures Feb 2017 58% 23% 19% novo nordisk

View entire presentation